CARMA Therapeutics is pleased to announce that Penn Medicine, a cellular therapy powerhouse and the cradle of the CARMA technology, has participated in a funding deal to support the Company’s efforts to bring new groundbreaking oncology treatments to market. Penn Medicine joins a group of top tier VCs, which provided initial capital to the company.
The financing was co-led by AbbVie Ventures and HealthCap with participation by Grazia Equity and IP Group Inc. CARMA Therapeutics is building a pipeline of cancer programs using its proprietary CARMA platform, combining chimeric antigen receptor targeting with macrophages to tackle solid tumors. The proceeds will be used primarily to advance the development of its first product, CARMA-0508, an adoptive cellular immunotherapy using chimeric antigen receptor macrophages (CARMA) for the treatment of metastatic solid tumors. For further information, click here.
Research on chimeric antigen receptor macrophages by CARMA Therapeutics co-founders Dr. Klichinsky and Dr. Gill drew significant interest at the AACR Annual Meeting in Washington, DC, April 1-5, 2017. The presented data demonstrate CARMA anti-tumor function in pre-clinical models of disseminated metastatic solid tumors.
CARMA Therapeutics engages Bruce A. Peacock as Executive Chairman to oversee early company operations and fundraising and build out the team. Bruce comes to CARMA with over 35 years of experience in the pharmaceutical industry including CEO, COO and CFO positions at public and private biotech companies including OrthoVita, Centocor, Cephalon and others.
Co-Founder Michael Klichinsky, PharmD presented a poster titled “Chimeric antigen receptor macrophages (CARMA) for adoptive cellular immunotherapy of solid tumors” at the Society for Immunotherapy for Cancer (SITC) Conference, November 9-13, 2016 in National Harbor, MD. Dr. Klichinsky received a Young Investigator Award from the Society “based on the quality of … research and potential to advance the field.”
CARMA Therapeutics was launched by co-founders Saar Gill, MD, PhD and Michael Klichinsky, PharmD through UPstart within PCI Ventures at the University of Pennsylvania to commercialize new cellular therapies based on chimeric antigen receptor targeting of macrophages. The company is located in Philadelphia, PA.